STOCK TITAN
  1. Home
  2. Sec-filings
  3. MESO
  4. [6-K] Mesoblast Limited American Current Report (Foreign Issuer)

[6-K] Mesoblast Limited American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock MESO logo
Mesoblast

NASDAQ:MESO

MESO Rankings

#2183 Ranked by Market Cap
N/A Ranked by Dividends

MESO Latest News

Aug 28, 2025
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
Aug 27, 2025
Mesoblast Financial Results and Corporate Update Webcast
Jul 17, 2025
Successful Commercial Launch of Ryoncil®
Jun 30, 2025
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
Jun 11, 2025
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

MESO Latest SEC Filings

Aug 29, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)
Aug 29, 2025
[20-F] Mesoblast Limited American Files Annual Report (Foreign Issuer)
Aug 27, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)
Jul 14, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)
Jul 1, 2025
[6-K] Mesoblast Limited American Current Report (Foreign Issuer)

MESO Stock Data

1.77B
128.03M
0.06%
2.69%
1.86%
Biotechnology
Healthcare
Link
Australia
Melbourne